GlaxoSmithKline

Selected Articles

2025-08-13

GlobeNewswire

Saudi Arabia Osteoporosis Drugs Market Analysis Report 2025-2033 Featuring Amgen, Eli Lilly and Co, F. Hoffmann La Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, Teva Pharmaceutical, UCB

2025-08-13

GlobeNewswire

Trends Shaping the $12+ Billion Teeth Whitening Industry 2025-2030: Innovative Technologies and Regulatory Updates Transforming the Global Market

2025-08-13

GlobeNewswire

Cytokines Market Forecast Report 2025-2030 | Revenues to Hit $145.25 Billion by 2030 | Detailed Insights by Type, Production, Formulation, Application, Country and Company

2025-08-13

GlobeNewswire

Antibody Drug Conjugate (ADC) Market Report 2025: Industry Set to Double by 2030 Driven by Next-Gen Oncology Innovations, Reaching $16 Billion

2025-08-12

GlobeNewswire

Chronic Hand Eczema Market Forecasts Report 2025-2035 | Emerging Markets, Safer Therapies, and Digital Health Solutions for Chronic Skin Conditions Spur Opportunities

2025-08-12

GlobeNewswire

Viral Vector Vaccines Strategic Business Research Report 2025 | Market to Reach $893.2 Million by 2030 - Pandemic-Era Acceleration of Vaccine Technologies Continues to Drive Viral Vector Advancements

2025-08-11

GlobeNewswire

Gastric Cancer Market on Growth Trajectory: Novel Therapies Drive Momentum Through 2034 | DelveInsight

2025-08-11

GlobeNewswire

GDAI 2025 Scales New Heights: 1,000+ Sessions, 70+ Global affiliate Partners, and a Powerhouse Speaker Lineup

2025-08-11

GlobeNewswire

Uncomplicated Urinary Tract Infections Pipeline Market Landscape Report 2025 | Therapeutic Assessments by Type and Stage, and the Latest in Clinical Development, Such As GSK's Gepotidacin in Phase III

2025-08-11

GlobeNewswire

Chronic Inflammatory Demyelinating Polyneuropathy Market Report 2025 | Distribution Channel, Route of Administration, and Region Analysis and Forecast to 2035

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development, as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. GB00BN7SWP63 www.gsk.com